- Home
- CRVS vs WALD Comparison
CRVS vs WALD Comparison
Compare CRVS & WALD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- WALD
- Stock Information
- Founded
- CRVS 2014
- WALD 1988
- Country
- CRVS United States
- WALD United States
- Employees
- CRVS N/A
- WALD N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- WALD Package Goods/Cosmetics
- Sector
- CRVS Health Care
- WALD Consumer Discretionary
- Exchange
- CRVS Nasdaq
- WALD Nasdaq
- Market Cap
- CRVS 305.4M
- WALD 306.3M
- IPO Year
- CRVS 2016
- WALD 2021
- Fundamental
- Price
- CRVS $5.75
- WALD $1.56
- Analyst Decision
- CRVS Strong Buy
- WALD Strong Buy
- Analyst Count
- CRVS 4
- WALD 5
- Target Price
- CRVS $15.00
- WALD $4.96
- AVG Volume (30 Days)
- CRVS 518.7K
- WALD 528.0K
- Earning Date
- CRVS 08-07-2025
- WALD 11-11-2025
- Dividend Yield
- CRVS N/A
- WALD N/A
- EPS Growth
- CRVS N/A
- WALD N/A
- EPS
- CRVS N/A
- WALD N/A
- Revenue
- CRVS N/A
- WALD $273,868,000.00
- Revenue This Year
- CRVS N/A
- WALD $10.37
- Revenue Next Year
- CRVS N/A
- WALD $14.37
- P/E Ratio
- CRVS N/A
- WALD N/A
- Revenue Growth
- CRVS N/A
- WALD 25.55
- 52 Week Low
- CRVS $2.54
- WALD $1.50
- 52 Week High
- CRVS $10.00
- WALD $4.40
- Technical
- Relative Strength Index (RSI)
- CRVS 65.10
- WALD 35.98
- Support Level
- CRVS $5.28
- WALD $1.50
- Resistance Level
- CRVS $5.64
- WALD $1.79
- Average True Range (ATR)
- CRVS 0.30
- WALD 0.16
- MACD
- CRVS 0.03
- WALD 0.00
- Stochastic Oscillator
- CRVS 77.70
- WALD 10.00
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About WALD Waldencast plc
Waldencast PLC is a beauty and wellness operating platform. The company is organized into two reportable segments namely Obagi Skincare and Milk Makeup. The company generates the majority of its revenue from the Obagi Medical segment. The Obagi Medical segment is engaged in developing, marketing, and selling skin health products. The Milk Makeup segment includes developing, marketing, and selling cosmetics, skincare, and other beauty products. Geographically the company generates the majority of its revenue from North America region.